ホーム › 多発性骨髄腫 › ニュージャージー

ニュージャージーにおける多発性骨髄腫の臨床試験

ニュージャージー内の拠点で、多発性骨髄腫に関する38件の研究が参加者を募集しています。

ニュージャージー内の都市

公式研究テキスト（英語）

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

被験者募集中第2相

60歳以上 · 全性別 · 2026/10/01更新 · NCT06679829

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Local Institution - 0363, Ridgewood

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT05519085

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Hackensack University Medical Center, Hackensack

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT04973605

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Astera Cancer Care, East Brunswick

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Astera Cancer Care, East Brunswick

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

MSK Basking Ridge, Basking Ridge
MSK Monmouth, Middletown
MSK Bergen, Montvale

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT05623020

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Hackensack University Medical Center, Hackensack
Rutgers Cancer Institute of New Jersey, New Brunswick

被験者募集中第4相

18歳以上 · 全性別 · 2026/09/25更新 · NCT05201781

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Hackensack Meridian Health - John Theurer Cancer Center, Hackensack

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/21更新 · NCT03909412

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

John Theurer Cancer Center, Hackensack

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/21更新 · NCT04661137

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Hackensack Meridian Health, Hackensack
Carol G Simon Cancer Center, Morristown

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/15更新 · NCT06976476

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Rutgers Cancer Institute of New Jersey, New Brunswick

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Hackensack University Medical Center, Hackensack

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/02更新 · NCT06988488

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/28更新 · NCT07075185

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Hackensack

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/27更新 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Atlantic Health System Morristown Medical Center, Morristown

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/24更新 · NCT06152575

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

MSK Basking Ridge, Basking Ridge
MSK Monmouth, Middletown
MSK Bergen, Montvale

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/24更新 · NCT05020236

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Jefferson Cherry Hill Hospital, Cherry Hill
Sidney Kimmel Cancer Center Washington Township, Sewell

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Hackensack University Medical Center, Hackensack

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/18更新 · NCT05651932

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/17更新 · NCT07105059

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, East Brunswick

被験者募集中第3相

18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Consent only), Middletown
Memorial Sloan Kettering Bergen (Consent Only), Montvale

被験者募集中観察研究

18歳以上 · 全性別 · 2026/08/06更新 · NCT07249528

Mosaic Trial for Stem Cell Transplant Recipients

Hackensack Meridian Health, Nutley

被験者募集中

18歳以上 · 全性別 · 2026/08/03更新 · NCT06960993

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/07/28更新 · NCT07099391

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

被験者募集中第1相

18歳以上 · 全性別 · 2026/07/16更新 · NCT06121843

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

被験者募集中第2相

18歳以上 · 全性別 · 2026/07/06更新 · NCT06083922

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

被験者募集中第2相

18歳以上 · 全性別 · 2026/06/16更新 · NCT07454382

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers Cancer Institute of New Jersey, New Brunswick
RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick

被験者募集中早期第1相

18歳以上 · 全性別 · 2026/05/29更新 · NCT04211259

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Rutgers Cancer Institute of New Jersey, New Brunswick

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/05/13更新 · NCT05828511

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Rutgers Cancer Institute of New Jersey /ID# 266833, New Brunswick

被験者募集中第1相

18歳以上 · 全性別 · 2026/05/12更新 · NCT06896916

A Dietary Study for People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

被験者募集中

18歳以上 · 全性別 · 2026/05/05更新 · NCT07226609

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site, Hackensack

被験者募集中第3相

18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Atlantic Health, Morristown
Rutgers Cancer Institute of New Jersey, New Brunswick

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

被験者募集中第2相

18歳以上 · 全性別 · 2026/03/04更新 · NCT06066346